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Serum and plasma calprotectin concentration is shown to be elevated when neutrophils are activated, and may
therefore be used as a marker for inflammatory diseases. A serum calprotectin immunoassay was developed based
on calprotectin values observed in samples from the intensive care unit. The polyclonal avian antibodies were
raised and affinity purified with calprotectin antigens. The performance was tested and it was observed that the
assay was linear in the range 0.3–24.7 mg/L, the limit of quantitation was observed to be lower than 0.3 mg/L, no
antigen excess was observed up to 54 mg/L, all CVs were lower than 1.8 % in the precision study, the calibration
curve stability was longer than 6 weeks, and there was no significant interference detected for haemoglobin,
intralipid or bilirubin. The serum calprotectin immunoassay presented in this paper performs well within the criteria
carefully set from the limited clinical experience obtained in both serum and plasma. In addition it is commutable
with Bühlmann MRP8/14 ELISA.Background
In clinical practice, the diagnosis of a bacterial infection
requiring antibiotic treatment is made from observation
of clinical symptoms, supported by leukocyte counts
and/or C-reactive protein (CRP) measurement. It has
been estimated that about 40 % of cases are misclassified
between bacterial infections and other causes [1]. Previ-
ously it has been shown that the neutrophil activation
marker HNL/NGAL could distinguish between acute
bacterial and viral infections with a sensitivity and speci-
ficity of more than 95 % [1].
Similar to HNL/NGAL, calprotectin is a neutrophil ac-
tivation marker. The plasma concentration of calprotec-
tin is higher than for HNL/NGAL. It is therefore easier
to develop calprotectin assays that can be applied on
standard chemistry analysers. Calprotectin is mostly
found in the neutrophils where it accounts for approxi-
mately 30–40 % of the cytosol protein content. Calpro-
tectin has been used as a marker for neutrophil
activation and has been shown to be elevated in inflam-
matory conditions where neutrophil activation is* Correspondence: tom.nilsen@gmail.com
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creativecommons.org/publicdomain/zero/1.0/involved [2]. Elevated levels of calprotectin have been
detected in blood and faeces, and calprotectin is consid-
ered to be an important inflammation marker [3, 4]. The
calprotectin molecule comprises of two members of the
S100 family; S100A8 (MRP8) and S100A9 (MRP14). Cal-
protectin thus contains these two subunits, but the exact
in vivo structure of calprotectin is debated. Johne et al.
suggest it is a heterotrimer [5], Pepper et al. suggest it is
a heterodimer [6], and Steinbakk et al. suggest it is a
hetero-tetramer when calcium is present [7]. In faeces,
elevated calprotectin concentrations are used as markers
for intestinal inflammatory diseases, such as inflammable
bowel disease (IBD) and Crohn’s disease among others
[8]. Fecal-calprotectin is widely used to discriminate be-
tween IBD and irritable bowel syndrome and the test is
thus used in large volumes. Serum calprotectin is not as
widely used as faecal calprotectin, but it has also been
used as an inflammatory marker. It has been reported to
be a valuable marker for sepsis [6, 9], and a marker for
acute appendicitis [10]. Bacterial infections usually cause
neutrophil activation, thus, in theory a neutrophil activa-
tion marker should be more specific for bacterial infec-
tions than e.g. CRP. The rapidly growing problem with
antibiotic resistance has resulted in demands for moreticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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markers that can better distinguish between bacterial
and viral infections. Sepsis patients may have low levels
of neutrophils in the blood as the neutrophil activation
causes the neutrophils to attach to the endothelium and
leave the circulation. This can be circumvented by using
a protein marker for neutrophil activation rather than
measuring the number of circulating neutrophils. ELISA
is the most used method for measuring Calprotectin,
but is usually associated with long test turnaround times.
In this study we have used the Calprotectin ELISA kit from
Bühlmann Laboratories AG, Schönenbuch, Switzerland for
comparison of patient results. ELISAs are usually also
more expensive than turbidimetric assays as they are more
labour intensive. Laboratories collect samples to fill up en-
tire microtiter plates, which could take several days, in
order to reduce reagent and labour costs. A particle en-
hanced turbidimetric immunoassay are usually used as a
random access test and the samples will be run continu-
ously as they arrive at the laboratory which will contribute
to reduced test turnaround times. The immunoparticles
developed for the Gentian Serum Calprotectin immuno-
particles were coated with polyclonal avian antibodies. The
antibodies were raised in hens which were immunised with
purified MRP8/MRP14 heterodimers. The polyclonal anti-
bodies are assumed to detect both monomers and di-
mers and even oligomers of the MRP8/MRP14
complex. Avian antibodies do not react with rheuma-
toid factors, human anti-mouse IgG antibodies
(HAMA) or the human complement system. These are
all well-known causes of erroneous test results in tests
based on mammalian antibodies. The aim of the
present study was to develop and validate a particle en-
hanced turbidimetric immunoassay (PETIA) for the de-
tection of human calprotectin in serum or plasma.Materials and methods
Reagents
The Gentian Serum Calprotectin Immunoassay re-
agents consist of immunopartcles, buffer, calibrators
and controls.Immunoparticles and reaction buffer
The Gentian Serum Calprotectin immunoparticles were
prepared by covalently attaching purified avian immuno-
globulin fractions to uniform polystyrene particles. The
avian immunoglobulin fractions were purified from eggs
from immunized hens. The antibodies were directed
against human calprotectin (hetero dimer of MRP8/
MRP14). Calprotectin extracted and purified from hu-
man granulocytes was used in the process of raising the
avian antibodies. The reaction buffer was a 3-(N-mor-
pholino)propanesulfonic (MOPS) buffer with pH = 7.2.Calibrators
Purified calprotectin was diluted in a phosphate buffer
pH = 7.4 to achieve six calibration levels: 0, 1, 3, 6, 15,
30 mg/L. The calprotectin concentration of the stem so-
lution was assigned by the Biuret method (Bioquant™,
Merck KGaA, Darmstadt, Germany).
Controls
Controls were prepared by adding purified calprotectin
to normal human serum. Two levels were prepared; 1.2
and 8.9 mg/L.
Instruments
The fully automated clinical chemistry instrument
Mindray™ BS-380 (Mindray Medical International,
Shenzhen, China) was used for all calprotectin
measurements.
Parameter settings were optimised for the Gentian
Serum Calprotectin Immunoassay on this instrument.
For the method comparison the Gentian Calprotectin
Immunoassay was compared to a MRP8/MRP14™ ELISA
kit from Bühlmann Laboratories AG, Schönenbuch,
Switzerland.
Applications/Assay procedures
A set of parameter settings were optimised for the Gen-
tian Serum Calprotectin Immunoassay on Mindray
BS380(™), Shenzhen, China. The parameter settings
were: sample volume = 3 μL, R1 volume = 200 μL and
the R2 volume = 30 μL. The wavelength was 605 nm and
the reading times 38/39-55/56, which is equal to 204 s
as each cycle counts 12 s.
The studies
To demonstrate the performance characteristics of the
Gentian Serum Immunoassay, a calibration curve was
established using the settings described above and con-
trolled by measuring the QC’s the same day as the stud-
ies were performed, unless otherwise specified. The
studies were based on the CLSI protocols.
Limit of quantitation (LoQ)
Four samples at different concentration levels ranging
from 0.2 to 0.6 mg/L were prepared by diluting a normal
serum sample in the calibrator matrix, these were ali-
quoted into 12 tubes of 300 μL and stored at −50 °C.
The samples were brought to room temperature, vor-
texed and measured directly. Four tubes of each concen-
tration level were measured in 4 replicates for 3 days. In
total, 36 measurements for each concentration level
were performed over 3 days with a recalibration and QC
measurements every day. The undiluted sample was
measured in 12 replicates the first day in order to
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luted samples.
CV’s and biases from theoretical values were calculated,
and the total error results were decided by the root
mean square method. LoQ was determined to be the
lowest calprotectin concentration sample where the total
error was lower than 20 %.
Antigen excess
Samples were prepared by spiking a pool of normal
serum with granulocyte extract to a calprotectin concen-
tration of approx 50 mg/L. A dilution series of 9 samples
was made from this spiked pool, ranging from 2.5 to
100 % of the original sample. All samples were measured
in duplicate. The antigen excess occurs at the lowest
concentration where the returned turbidimetric results
are below the value of the turbidimetry result of the
highest calibrator. A result above the highest calibration
point will force the instrument to flag the sample and
the user will be notified by alarm to start a diluted rerun
if needed.
Linearity
The preparation of the linearity series was carried out by
preparing a high calprotectin serum sample and a low
calprotectin serum sample. The high sample was pre-
pared by spiking a normal serum sample, to a concentra-
tion of 20–30 mg/L, with granulocyte extract containing
high levels of calprotectin. The low sample was prepared
by diluting a normal serum sample with saline to a con-
centration below 0.5 mg/L. A dilution series was pre-
pared by mixing the high serum sample with the low
serum sample in the range from 100 to 0 %. Ten sam-
ples in the series were prepared. The 100 % serum sam-
ple and the 0 % serum sample were measured in
triplicate in order to get assigned values. The expected
value of each sample in the series was then calculated
from the assigned values and dilution factors. All sam-
ples were measured in duplicates. The deviation from
expected values was calculated. The acceptable deviation
from the theoretical values was set to be less than 10 %.
Precision and calibration curve stability
Three samples, and 2 controls (low and high), were dis-
pensed into 14 aliquots of 300 μL, and stored in cryo
tubes below −55 °C, the concentrations of these spanned
the calibration curve. At day one the calibration curve
was established. The samples were brought to room
temperature, vortexed and measured immediately in du-
plicate. This procedure was repeated for 10 subsequent
working days, without recalibration. Total CV’s were cal-
culated. The reagents were stored on-board during the
study period. The established calibration curve was fur-
ther applied to measure the same samples every weekfor up to 4 more weeks after the last day of the precision
study to investigate the calibration curve stability of the
immunoassay.
Interference
The purpose of this study was to determine if haemoglo-
bin, intralipid or bilirubin interfere with the calprotectin
immunoassay on Mindray BS-380™.
The goal was to demonstrate that the assay does not
interfere with these substances at the following concen-
trations: Bilirubin up to 400 mg/L, Haemoglobin up to
5 g/L, Intralipid up to 10 g/L. The haemoglobin samples
were prepared by adding 0.106 ml of 94 g/L hemolysate
to 1.894 ml of serum. The control sample was prepared
by adding 0.106 ml of saline in 1.894 ml of serum. No
significant interference is defined as less than 10 % dif-
ference between test and control samples.
Method comparison
In total 60 samples were measured on both Gentian Cal-
protectin Immunoassay and Bühlmann ELISA the same
day. Bühlhmanns ELISA has a measuring range from 0.4
to 24 mg/L. The samples measured were distributed
over the ELISA calibration curve with a predominance
of samples between the lower reference interval up to
approximately 6.5 mg/L. The samples were first mea-
sured on the Gentian Serum Calprotectin Immunoassay
and then immediately measured on the ELISA. The re-
sults were evaluated using Analyse-It(™) for Excel,
Analyse-It Software, Ltd, Leeds UK. For the ELISA the
duplicates could vary significantly. The observed repli-
cates that deviated by more than 25 % were defined as
outliers and removed from the data set.
Lot variation
Two immunoparticle batches were prepared with two
different antibody batches, where the antibodies were
raised using two separately prepared antigens. The re-
sults were evaluated using Analyse-It™ for Excel, (Ana-
lyse-It Software, Ltd, Leeds UK).
Patient samples
P-calprotectin was analyzed in Li-heparin plasma from
50 blood donors; 17 females (age 18–65) and 33 males
(age 21–75 years) and 13 patients with sepsis; three fe-
males (age 26–45) and ten males (age 40–88 years).
Results
Limit of quantitation
The lower quantitation limit (LoQ) was defined as the
lowest sample with a total error less than 20 %. For the
serum calprotectin assay the LoQ was observed to be
0.35 mg/L. The total error for this sample was 15.9 %.
Table 1 shows the results from all samples tested.
Table 1 Determination of the lower limit of quantitation of the
calprotectin assay
Mean (mg/L) 1,316 0,624 0,489 0,347 0,206
std (mg/L) 0,0198 0,0340 0,0336 0,0400 0,0344
CV (%) 1,5 5,4 6,9 11,5 16,7
Theoretical value (mg/L) 1,32 0,66 0,53 0,40 0,26
Deviation from theoretical
value (mg/L)
−0,004 −0,036 −0,039 −0,049 −0,058
TE 0,0202 0,0494 0,0518 0,0631 0,0678
TE% 1,5 7,5 9,8 15,9 25,7
The results are presented as CV and deviation from theoretical value. The
lowest concentration with an acceptable total error was 0.37 mg/L
Fig. 2 The observed data from the prepared linearity series with a
linear fit. The observed values measured on a dilution series
prepared by diluting a high calprotectin concentration serum
sample with a low concentration serum sample were compared
to the expected values. The observed values are on the y-axis and
the expected on the x-axis. The expected values were calculated
from dilution factors and the assigned values to the high sample
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The prepared series were measured in duplicate and the
mean values were plotted in Fig. 1. All observed results
from sample concentrations in the range 30−54 mg/L
were above the highest calibrator value, which was
30 mg/L. No antigen excess from concentrations below
54 mg/L was observed.(24.7 mg/L) and the low sample (0.3 mg/L)Linearity
There were no observations deviating more than 5 %
from expected values when measuring the prepared lin-
earity series. The observed data are presented in Fig. 2
and Table 2. This is within the predefined criteria of
±10 % from the expected values calculated from the
assigned values of the 0 % sample and the 100 % sample,
and the dilution factors.Fig. 1 Measured values of a diluted series made from a high
concentration sample spiked to 54 mg/L. All samples with
concentrations between 30 mg/L and 54 mg/L is measured to be
above the highest calibration standard and will therefore go to
rerun automatically. Hence there is no antigen excess observed
for samples up to 54 mg/LPrecision
The 10 day precision study showed CVs lower than
1.5 % for all samples ranging from 1.17 mg/L up to
22.14 mg/L. The samples were measured on 10 subse-
quent working days. The data are presented in Table 3.
Calibration curve stability
The observation of the measured samples over time,
shown in Figs. 3 and 4, suggests a calibration curve sta-
bility of at least 6 weeks. The total CV for all samplesTable 2 Linearity study by diluting a sample with a high
calprotectin concentration in a sample with low calprotectin
concentration






100 24,70 24,76 100,2
80 19,82 19,40 97,9
60 14,95 14,46 96,7
40 10,07 9,90 98,3
20 5,20 5,34 102,8
10 2,76 2,77 100,3
5 1,54 1,48 95,9
2,5 0,93 0,91 97,9
1,5 0,69 0,66 95,8
0 0,32 0,31 96,9
The observed values were compared with the expected values and the
recovery was calculated. The observed data from the linearity series deviated
less than ±5 % from the expected values calculate from the assigned values of
the 0 % sample and the 100 % sample and the dilution factors
Table 3 The daily means, total means, standard deviations and total CV’s from the precision study










Day 1 1,17 6,82 22,65 1,22 8,78
Day 2 1,16 6,64 22,25 1,21 8,57
Day 3 1,17 6,68 22,11 1,19 8,55
Day 4 1,18 6,69 22,27 1,22 8,56
Day 5 1,19 6,67 22,14 1,19 8,55
Day 6 1,17 6,66 22,27 1,17 8,59
Day 7 1,17 6,68 21,98 1,20 8,62
Day 8 1,16 6,66 21,83 1,19 8,60
Day 9 1,21 6,73 21,95 1,22 8,59
Day 10 1,18 6,69 22,03 1,18 8,61
Total mean 1,17 6,69 22,14 1,20 8,60
Total Stdev 0,0147 0,0523 0,2303 0,0174 0,0680
Total CV 1,3 0,8 1,0 1,4 0,8
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4 and 5 were 1.17, 6.82, 22.65, 1.22 and 8.78 mg/L re-
spectively at baseline.
Method comparison
The method comparison data shows that the tubidimetric
calprotectin immunoassay is commutable with the Bühl-
mann ELISA, see Fig. 5. In order to demonstrate the com-
mutability with a better Passing Bablok regression fit, it
was appropriate to apply a factor of 3 on the Gentian data.
As shown in Fig. 6, the regression fit was then acceptable
with an intercept of −0.17 and a slope of 0.96.
Lot variation
The two batches of immunoparticles prepared with two
different antibodies, raised against different antigenFig. 3 Samples 2, 3 and 5 measured within the range of baseline
±10 % for all 6 weeks. From the observed results, the tubidimetric
serum calprotectin immunoassay can claim 6 week of calibration
curve stability for samples higher than 6 mg/Lpreparations, correlate well. Figure 7 shows the data
with Passing Bablok regression fit. The equation of the
fit was 1.00× − 0.09.Interference
None of the three substances interfere significantly at
tested levels, see Table 4. The maximum allowed differ-
ence between the test and control samples was decided
to be 10 % from the value of the control sample.Analysis of patient samples
The median P-calprotectin value in the blood donor group
was 0.80 mg/L (Interquartile range (IQR) 0.37–1.19 mg/L)
while the median P-calprotectin value in the sepsis group
was 4.18 mg/L (IQR 2.51–8.32). The difference betweenFig. 4 Samples 1 and 4 measured within the range of baseline
±10 % for all 6 weeks. From the observed results, the turbidimetric
serum calprotectin immunoassay can claim 6 week of calibration
curve stability for samples higher than 6 mg/L
Fig. 5 60 samples were measured on both Bühlmann MRP8/MRP14
ELISA and the turbidimetric serum calprotectin immunoassay. The
comparison with the results from the ELISA on the x-axis and the
results from the turbidimetric assay on the y-axis shows that the two
methods correlate well and are highly commutable
Fig. 7 Comparing two preparations with two different batches of
antibodies raised and purified with different calprotectin antigens in
different hen batches, indicates a low lot to lot variation. The results
from the two batches of immunoparticles correlate well
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Test (p = 0.003).
Discussion
Antibiotic resistance is generally accepted as one of the
greatest threats to our health. It is thus essential to slow
the emergence of resistance and extend the useful lifetime
of antibiotics. A goal set for 2020 by the United States
Centers for Disease Control and Prevention (CDC) is a re-
duction of inappropriate antibiotic use by 50 % in out-
patient settings and by 20 % in inpatient settings [11]. To
be able to reach this goal we need new markers that accur-
ately can distinguish between bacterial and viral infections.
Identification of a biomarker able to clearly distinguishFig. 6 A factor 3 was multiplied by the results from the turbidimetric
assay. The results were then compared to the results from the Bühlmann
MRP8/MRP14 ELISA. Applying a factor 3 to the data measured on
Gentian’s method improved the Passing Bablok linear regression fit and
demonstrates the commutability between the methodsbacterial from non-infectious systemic inflammation is im-
perative. The development of new biomarkers takes sev-
eral years and it is thus important that we now start the
development and evaluation of new markers. Neutrophil
activation markers such as calprotectin, alone or in com-
bination with other inflammation markers, could poten-
tially be superior to e.g. CRP to distinguish between
bacterial and viral infections.
Sepsis is an acute condition that requires rapid treat-
ment. If new markers are to be useful they need to be
available with short test turn-around times at all
hours. It is also important that the tests can be run at
as many hospitals as possible either as centralized as-
says or as POC tests. The purpose of this paper is to
validate the technical performance of a new serum cal-
protectin turbidimetric immunoassay, which hopefully
will make measurement of serum calprotectin more
available. The method can easily be applied on the
chemistry analyzers that are standard instrumentation
in hospital laboratories. As this is a new assay it was
important to validate the performance of the turbidi-
metric assay. It is important that the measuring range
is suitable for patient samples to avoid excessive re-
runs or antigen excess problems. The most severe
cases of sepsis are usually treated in the intensive care
unit. To verify the suitability of the measuring range
we analyzed consecutive samples from the intensive
care unit. None of the samples had calprotectin values
higher than 25 mg/L and we did not observe any anti-
gen excess problems. The assay measured accurately
down to 0.35 mg/L as shown in the LoQ study. In an
earlier published study [12], the reference interval of
serum calprotectin was found to be 0.5–2.5 mg/L.
Thus, the majority of patient samples will be within
Table 4 Interference of haemoglobin, intralipid and bilirubin was tested by adding these substances to patient samples











Hemoglobin - low 5 g/L 1,54 1,46 0,08 0,15 yes
Hemoglobin - high 5 g/L 10,06 9,92 −0,14 0,99 yes
Intralipid - low 10 g/L 1,48 1,37 −0,11 0,15 yes
Intralipid - high 10 g/L 9,71 9,7 −0,01 0,97 yes
Bilirubin - low 400 mg/L 1,52 1,5 −0,02 0,15 yes
Bilirubin - high 400 mg/L 10,02 10,01 −0,01 1,00 yes
The calprotectin values before and after addition was compared. A difference of ≤10 % was the criteria for acceptance. None of the substances had significant
interference at tested levels
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54 mg/L all measured above the highest calibrator
standard, which was 30 mg/L. This means there is no
risk of antigen excess problems up to 54 mg/L. During
this project there were no patient samples observed
above 29 mg/L, based on this experience, the assay
will most likely not run into problems when it comes
to antigen excess. There were no significant interfer-
ences by haemoglobin, lipids or bilirubin and the coef-
ficient of variations were below 1.8 % which is lower
than for most ELISA methods. Gentian serum calpro-
tectin assay is based on polyclonal avian antibodies in
contrast to Bühlmanns MRP8/MRP14 ELISA, which is
based on mammalian monoclonal antibodies. This can
explain some of the spread in the method comparison
plot. Polyclonal antibodies will be able to detect and
add to the signal any composition of MRP8/MRP14
complexes. Monomers will for instance to some de-
gree be detected and add signal to the measurement.
The monoclonal based ELISA will only detect and
measure the dimer MRP8-MRP14 according to the
manufacturer. There is no international standard for
serum calprotectin, which forces the manufacturers to
rely on internally established standards to avoid lot to
lot variation. Since the method to assign value to these
internal standards is of free choice, there will be differ-
ent levels of the standards among the manufacturers
depending on which method they choose. We believe
this is the cause of the difference between the mea-
sured values of Gentian’s assay and the Bühlmann
ELISA. The commutability shown in the method com-
parison study demonstrates that these two methods
can easily be adjusted to measure on the same levels if
required.
Conclusions
The serum calprotectin immunoassay presented in this
paper performs well within the criteria. With this assay
it should not be expected to observe any antigen excess,
sensitivity limitations or linearity problems within any
part of the observed measuring range. The precision isgood and the there is no significant interference ob-
served with haemoglobin, bilirubin or intralipid. The
method comparison shows that the method is commut-
able with Bühlmann MRP8/14 ELISA and will correlate
well when the calibrators are adjusted to an international
standard in the future.
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